MedCity Influencers

The BCI Race Everyone is Watching May Be the Wrong One

The technology race gets the attention. Another race may determine what becomes the new standard of care.

In February 2025, Medtronic received FDA approval for BrainSense Adaptive deep brain stimulation (DBS), a closed-loop system that reads a patient’s neural signals and adjusts therapy in real time. Medtronic described the U.S. rollout as the largest commercial launch of brain-computer interface (BCI) technology ever undertaken.

Yet almost no one includes Medtronic when they talk about the BCI race — and that’s worth paying attention to.

Why? Because BrainSense entered healthcare as something the market already understood: better DBS. The patient was known. The problem was recognized. The intervention was accepted. Referral and reimbursement pathways already existed.

presented by

That points to something I think we’re underestimating in the BCI race.

When people talk about BCI today, they tend to compare Neuralink, Synchron, Precision Neuroscience, Paradromics, Blackrock Neurotech, INBRAIN Neuroelectronics, and a growing field of newer entrants. 

Everyone is understandably mapping companies against companies and architecture against architecture: penetrating versus surface versus endovascular, signal fidelity versus intervention burden, electrode count, bandwidth, patients implanted.

But there may be another map that matters just as much: each potential BCI application against the standard of care it would have to displace — or create.

presented by

BCI may be more like AI than a single medtech category

Think about AI. We don’t expect one AI application to win and become “the AI market.” It is an enabling capability being applied to hundreds of different problems, each with its own users, competitors and path to adoption.

BCI may evolve similarly.

The same underlying capability can restore communication, enable digital or environmental control, restore movement, map the brain or adapt a therapy in response to neural activity.

Those applications may share a technology, but they don’t necessarily share a market.

And in healthcare, the difference between the two is the whole ballgame. The ability to do something new does not, by itself, give the market a reason to change what it already does and trusts.

The unmet need isn’t the question

For people living with severe paralysis, ALS and other devastating neurological conditions, the unmet need is profound. The case for continuing to innovate is clear.

But that need alone doesn’t determine whether or when an innovation scales. An extraordinarily new technical capability still has to become part of what the healthcare system routinely does for a particular patient. Clinical breakthroughs and market adoption are not the same thing. 

Clinicians have to recognize which patients should be considered. Patients and families have to develop confidence in an intervention. Someone has to refer. The expected benefit has to justify the intervention. Payers need a basis for coverage. Eventually, those decisions have to become repeatable enough that the new approach becomes the expected course of care.

That’s the true journey from innovation to a new standard of care.

And every potential BCI application begins that journey against a different status quo.

  • So what happens if we map the landscape that way?
  • Where do existing approaches leave the clearest unresolved gap?
  • For which patients can BCI do something consequential that current care cannot?
  • What would the market have to believe before intervention becomes reasonable?
  • What evidence would create conviction in a different way forward?
  • Which behaviors would have to change—identification, referral, coverage, intervention—for adoption to occur?

And where could those behaviors become routine enough that the question eventually changes from “Why would we consider BCI for this patient?” to “Why wouldn’t we?”

That’s a very different race.

New standards usually start narrow

The strongest starting point may not be the largest potential market. It may be where the case for changing care is clearest.

It’s where current care leaves an unmistakable gap. Where the patient can be clearly identified. Where the benefit matters enough to justify intervention. Where the evidence can create conviction. And where clinicians and payers can agree on what success looks like.

Establish that first, and something important changes. BCI is no longer merely capable of producing an outcome. The market begins to expect that outcome for a particular kind of patient.

From there, the patient population can broaden. The intervention threshold can move. Referral pathways can expand. Evidence can accumulate. What begins narrowly can become routine.

That is how a new standard gets a foothold—and the market starts reinforcing it.

Some of those decisions are being made now

This isn’t simply a future commercialization question.

The Implantable BCI Collaborative Community is already developing outcome measures, practice guidance and payer frameworks—and CMS and FDA’s proposed RAPID pathway would bring coverage considerations earlier into evidence development. Some of the beliefs that will eventually become market rules are beginning to harden into criteria now.

A recent Health Affairs analysis makes the stakes tangible: demonstrations of environmental control or gaming may prove technical capability without necessarily establishing medical necessity for Medicare beneficiaries. Communication, by contrast, already has coverage precedent.

What the market learns to value will help determine which technical advantages become commercially consequential.

A breakthrough in bandwidth, invasiveness or signal fidelity can create extraordinary possibilities, but its commercial value ultimately depends on where those possibilities change what the market believes should happen for a patient—and then change what the market essentially does.

The other BCI race

Which brings us back to Medtronic.

BrainSense didn’t need to create the idea that neural technology belonged in care. It advanced a standard that was already there.

While much of the field is debating which technical architecture will ultimately win, the more consequential contest may be taking shape somewhere else:

  • Which application can create the clearest case for changing care and establish a new expectation of care?
  • Which can turn that expectation into new clinical, referral and coverage behavior?
  • And which can make those behaviors durable enough to become the new standard?

The technology race will determine what BCI can do. The market will determine which applications become standards of care.

Photo: Urupong, Getty Images

Holley Miller is a commercialization strategist and advisor to life sciences companies bringing products to market. As founder and president of Grey Matter Marketing, the first healthcare category design firm, she works with CEOs, boards and investors to challenge a common assumption, that clinically better products get adopted because they are better.

Her work centers on what she calls the Product Adoption Lie. Markets do not buy what is best. They buy what they already believe. Her approach helps leadership teams design the market before they scale, aligning clinical, regulatory and commercial functions around why adoption should happen now.

Before founding the firm in 2006, Holley held senior commercial roles in medical device and pharma. At Allergan, she led a repositioning that quadrupled revenue over four years by changing how the market understood the problem, not the science. Her work has contributed to more than $4.5 billion in enterprise value.

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.